Pharmaceutical giant breaks ground on $3.5B site in Lehigh Valley

© Office of Gov. Josh Shapiro

Pharmaceutical giant Eli Lilly and Company announced it had broken ground on a $3.5 billion manufacturing site in Pennsylvania’s Lehigh Valley.

The site is one of 10 new U.S. manufacturing sites announced by the company since 2020, and one of four among them dedicated to injectable medicines and devices, and is part of the company’s $50 billion move to expand medicine production. The Lehigh Valley site will add capacity for the next generation of obesity treatments, including retatrutide, an investigational GIP, GLP-1 and glucagon triple hormone receptor agonist.

“Obesity is one of the biggest health challenges of our time, and the science to treat it is moving quickly,” David A. Ricks, Lilly chair and CEO, said. “Retatrutide is one of several next-generation medicines we’re developing that could help millions more people living with obesity, type 2 diabetes, or both. This $3.5 billion investment means we’ll be able to make these medicines in Pennsylvania for people here at home and around the world.”

Lilly said it is working with the Upper Macungie Township Community Fund on an anticipated new community initiative where Lilly will provide up to $1 million over five years to support the development of a new quality-of-life program for Lehigh Valley families, with a focus on nutrition and healthy living, fresh food access, health resources, and community programming.

Additionally, the company said it is currently hiring in the Lehigh Valley and expects the new facility to create 850 high-wage jobs, along with an estimated 2,000 construction jobs as the site is built.

“Today marks another historic milestone in Pennsylvania’s thriving life sciences sector and reinforces my Administration’s commitment to advancing innovation, strengthening the economy, and creating good-paying jobs across the Commonwealth,” Gov. Josh Shapiro said. “We secured this historic, life-changing investment thanks to Pennsylvania’s world-class workforce, research institutions, infrastructure, and resources, and my Administration will continue working hard to ensure Pennsylvania remains a place where groundbreaking discoveries can translate into meaningful economic opportunities and results for patients and families.”